Posted on December 7, 2018 GLATECTTM IS NOW COVERED BY THE PROVINCIAL DRUG PLAN IN BRITISH COLUMBIA FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS). Read More
Posted on November 12, 2018 PENDOPHARM, a division of PHARMASCIENCE INC wins the D.W. BOLE award Read More
Posted on February 20, 2018 PENDOPHARM a division of Pharmascience signs an agreement with Cosmo Pharmaceuticals Read More
Posted on October 5, 2017 PENDOPHARM launches GLATECT, a new treatment option for MS patients Read More
Posted on September 22, 2017 PENDOPHARM, a division of Pharmascience Inc., Invests in Ontario based Edesa Biotech and Licenses Three Novel Anorectal Treatments for Canada Read More